MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

17.36 +0.84 (+5.08%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,687,063
Open	16.29
Bid (Size)	16.92 (200)
Ask (Size)	17.39 (200)
Prev. Close	16.52
Today's Range	16.02 - 17.53
52wk Range	5.950 - 62.75
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Performance

YTD	+45.3%	+45.3%
1 Month	-1.9%	-1.9%
3 Month	+45.3%	+45.3%
6 Month	+132.7%	+132.7%
1 Year	-54.4%	-54.4%

More News

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

Via The Motley Fool

MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗

January 09, 2026

Via Stocktwits

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Via The Motley Fool

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Via Stocktwits

MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗

February 22, 2026

Via Stocktwits

MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗

February 19, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗

February 18, 2026

Via Stocktwits

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗

February 17, 2026

Via Stocktwits

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

February 10, 2026

From ImageneBio, Inc.

Via GlobeNewswire

BioTech Breakout: MoonLake Up 30% On FDA Wins ↗

February 03, 2026

Via MarketBeat

MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗

January 15, 2026

Via Stocktwits

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

Via MarketMinute

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗

January 08, 2026

Via Stocktwits

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

December 15, 2025

From DJS Law Group

Via Business Wire

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

December 15, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 15, 2025

From The Schall Law Firm

Via Business Wire

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

December 13, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

December 12, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

December 12, 2025

Via TheNewswire.com

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?

Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.

What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?

MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?

The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market

What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?

The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 17.36

When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?

The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 04/02/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.